Evaluating Clinic-Based Interventions to Reduce Racial Differences in Mortality Among People With Human Immunodeficiency Virus in the United States
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Mortality remains elevated among Black versus White adults receiving human immunodeficiency virus (HIV) care in the United States. We evaluated the effects of hypothetical clinic-based interventions on this mortality gap.
METHODS: We computed 3-year mortality under observed treatment patterns among >40 000 Black and >30 000 White adults entering HIV care in the United States from 1996 to 2019. We then used inverse probability weights to impose hypothetical interventions, including immediate treatment and guideline-based follow-up. We considered 2 scenarios: "universal" delivery of interventions to all patients and "focused" delivery of interventions to Black patients while White patients continued to follow observed treatment patterns.
RESULTS: Under observed treatment patterns, 3-year mortality was 8% among White patients and 9% among Black patients, for a difference of 1 percentage point (95% confidence interval [CI], .5-1.4). The difference was reduced to 0.5% under universal immediate treatment (95% CI, -.4% to 1.3%) and to 0.2% under universal immediate treatment combined with guideline-based follow-up (95% CI, -1.0% to 1.4%). Under the focused delivery of both interventions to Black patients, the Black-White difference in 3-year mortality was -1.4% (95% CI, -2.3% to -.4%).
CONCLUSIONS: Clinical interventions, particularly those focused on enhancing the care of Black patients, could have significantly reduced the mortality gap between Black and White patients entering HIV care from 1996 to 2019.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:228 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 228(2023), 12 vom: 20. Dez., Seite 1690-1698 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zalla, Lauren C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiretroviral therapy |
|---|
| Anmerkungen: |
Date Completed 22.12.2023 Date Revised 20.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiad263 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359379516 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359379516 | ||
| 003 | DE-627 | ||
| 005 | 20240421231930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiad263 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1382.xml |
| 035 | |a (DE-627)NLM359379516 | ||
| 035 | |a (NLM)37437108 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zalla, Lauren C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluating Clinic-Based Interventions to Reduce Racial Differences in Mortality Among People With Human Immunodeficiency Virus in the United States |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2023 | ||
| 500 | |a Date Revised 20.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Mortality remains elevated among Black versus White adults receiving human immunodeficiency virus (HIV) care in the United States. We evaluated the effects of hypothetical clinic-based interventions on this mortality gap | ||
| 520 | |a METHODS: We computed 3-year mortality under observed treatment patterns among >40 000 Black and >30 000 White adults entering HIV care in the United States from 1996 to 2019. We then used inverse probability weights to impose hypothetical interventions, including immediate treatment and guideline-based follow-up. We considered 2 scenarios: "universal" delivery of interventions to all patients and "focused" delivery of interventions to Black patients while White patients continued to follow observed treatment patterns | ||
| 520 | |a RESULTS: Under observed treatment patterns, 3-year mortality was 8% among White patients and 9% among Black patients, for a difference of 1 percentage point (95% confidence interval [CI], .5-1.4). The difference was reduced to 0.5% under universal immediate treatment (95% CI, -.4% to 1.3%) and to 0.2% under universal immediate treatment combined with guideline-based follow-up (95% CI, -1.0% to 1.4%). Under the focused delivery of both interventions to Black patients, the Black-White difference in 3-year mortality was -1.4% (95% CI, -2.3% to -.4%) | ||
| 520 | |a CONCLUSIONS: Clinical interventions, particularly those focused on enhancing the care of Black patients, could have significantly reduced the mortality gap between Black and White patients entering HIV care from 1996 to 2019 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a antiretroviral therapy | |
| 650 | 4 | |a cohort studies | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a racial disparity | |
| 700 | 1 | |a Cole, Stephen R |e verfasserin |4 aut | |
| 700 | 1 | |a Eron, Joseph J |e verfasserin |4 aut | |
| 700 | 1 | |a Adimora, Adaora A |e verfasserin |4 aut | |
| 700 | 1 | |a Vines, Anissa I |e verfasserin |4 aut | |
| 700 | 1 | |a Althoff, Keri N |e verfasserin |4 aut | |
| 700 | 1 | |a Marconi, Vincent C |e verfasserin |4 aut | |
| 700 | 1 | |a Gill, M John |e verfasserin |4 aut | |
| 700 | 1 | |a Horberg, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Silverberg, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Rebeiro, Peter F |e verfasserin |4 aut | |
| 700 | 1 | |a Lang, Raynell |e verfasserin |4 aut | |
| 700 | 1 | |a Kasaie, Parastu |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Richard D |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Jessie K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 228(2023), 12 vom: 20. Dez., Seite 1690-1698 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:228 |g year:2023 |g number:12 |g day:20 |g month:12 |g pages:1690-1698 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiad263 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 228 |j 2023 |e 12 |b 20 |c 12 |h 1690-1698 | ||